DNA Diagnostics Market by Product Type (Instruments, Reagents, Service & Software), Technology (PCR, Microarray, In-situ Hybridization, Sequencing Technology, Mass Spectrometry), Application (Infectious Disease (Hepatitis B Virus, Hepatitis C Virus, HIV, TB, CT/NG, HPV, MRSA), Myogenic Disorder, Prenatal Diagnostics, Pre-implantation Diagnostics) — Global Opportunity Analysis and Industry Forecast, 2013–2020
GET FREE SAMPLE @ https://www.alliedmarketresearch.com/request-sample/298
The latest figures suggest that approximately 8.2 million people are living with cancer and 39 million with HIV. These numbers are set to increase consistently; however, advanced automated DNA diagnostics technologies such as next generation sequencing could play a crucial role in diagnosing and curbing these diseases. "Next generation sequencing has had a significant impact on diagnostic procedures and is set to gain momentum in the foreseeable future.
“Next generation sequencing not only reduces the cost of sequencing, but increases the throughput as well; it could thus help in bridging the gaps in traditional and personalized medications”, adds the analyst. This makes it a promising investment opportunity for key players. Illumina Inc.’s new cost-effective genome machine HiSeq X Ten -the world’s first DNA crunching supercomputer- is leading to a significant reduction in the price of sequencing a human genome.
DNA diagnostics Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $19 billion by 2020, registering a CAGR of 9.8% during the period 2014-2020. The potential to provide accurate diagnosis and cost effectiveness over alternative diagnostic techniques are factors which supplement the growth of the DNA diagnostics market.
Market analysis in terms of geography suggests that developed economies would retain their dominance in the market. This could be attributed to the early adoption of the technology due to potential reduction offered by DNA diagnostic to their high healthcare expenditure. However, developing economies, such as in Asia-Pacific, will significantly influence the DNA diagnostic market during the extended forecast period (2020–2025), largely due to potential growth in per capita healthcare expenditure and very large undiagnosed population.
Several companies operating in this region are seeking novel technologies to gain traction in the competitive market. Product launch is the key strategy adopted by companies operating in this market. These companies are developing novel products for the treatment of various diseases such as infectious diseases, cancer, prenatal diagnosis, pre-implantation diagnostics and myogenic disorder. Additionally, these companies are also adopting collaboration and acquisition to retain their respective positions and to gain traction in the market. Key companies profiled in the report are Bayer Diagnostic, Sysmex, Roche Diagnostics, Abbott laboratories, Cephide, Gene-probe Inc., Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Johnson and Johnson, and Novartis.
READ MORE @ https://www.alliedmarketresearch.com/dna-diagnostics-market
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
RELATED REPORTS
